|Videos|April 14, 2022
Combining Phenotypic Biomarkers and PET Imaging for Diagnosis and Treatment Selection
Author(s)Scott Tagawa, MD, MS, FACP, FASCO
A focused discussion on how phenotypic biomarkers and positron emission tomography (PET)-based imaging can be combined to diagnose and treat prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5